Streetbeat News

Products Services

AVO

BKSY

HYZN

MTRX

ORCL

U.S. stock futures are trading higher, with Oracle, BlackSky Technology, Mission Produce, Hyzon Motors, and Matrix Service being key stocks to watch. Oracle and Mission Produce are set to report earnings, while BlackSky surged due to a NASA award. Hyzon announced a reverse stock split.

Portfolio Pulse from Avi Kapoor

September 09, 2024 | 8:10 am

TSLA

Elon Musk denied reports of a revenue-sharing deal between Tesla and his AI startup xAI. He stated that Tesla has benefited from discussions with xAI engineers but does not need to license xAI's technology. The Wall Street Journal had reported potential licensing and revenue-sharing agreements between the two companies.

Portfolio Pulse from Anan Ashraf

September 09, 2024 | 8:06 am

AZN

AstraZeneca and Daiichi Sankyo's drug, Datopotamab Deruxtecan, showed significant improvement in progression-free survival for non-small cell lung cancer patients with the TROP2 biomarker in the TROPION-Lung01 Phase 3 trial.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 8:04 am

IMVT

Immunovant, Inc. reported positive Phase 2a trial results for its Graves' Disease drug, batoclimab, and received FDA clearance for a pivotal trial. The company highlighted unmet needs in the market for ATD-treated patients.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:59 am

AAPL

Apple is set to launch the iPhone 16, which could trigger the biggest upgrade cycle in its history, according to Wedbush analyst Dan Ives. The integration of AI is expected to drive this supercycle, with initial shipments projected to exceed expectations. Ives maintains an outperform rating on Apple stock with a price target of $285.

Portfolio Pulse from Kaustubh Bagalkote

September 09, 2024 | 7:54 am

LBPH

Longboard Pharmaceuticals reported interim results from its Phase 1b/2a PACIFIC study, showing a 57.7% reduction in seizures for DEE patients treated with Bexicaserin. The drug demonstrated favorable safety and tolerability. Full data is expected early next year.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:51 am

SVRA

Savara presented positive Phase 3 trial results for Molgramostim in treating autoimmune pulmonary alveolar proteinosis, showing significant improvements in disease severity and lung function compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:45 am

AAPL

Top analyst Ming-Chi Kuo has updated the production data for Apple's iPhone 16 series, forecasting shipments of 88-89 million units in 2024. The iPhone 16 series is expected to see a 10% YoY growth in Q3 2024 but a decline in Q4 2024 and Q1 2025. Foxconn and Luxshare ICT are the main EMS providers. Despite mixed expert opinions, the iPhone 16 launch is anticipated to boost Apple's stock.

Portfolio Pulse from Ananya Gairola

September 09, 2024 | 7:35 am

AAPL

Jim Cramer has identified Apple as the 'most vulnerable' among the Magnificent 7 stocks ahead of the iPhone 16 launch, citing concerns about overvaluation and high expectations from its partnership with OpenAI. The upcoming 'Glowtime' event is highly anticipated, but competition and mixed analyst opinions could impact Apple's stock performance.

Portfolio Pulse from Benzinga Neuro

September 09, 2024 | 7:27 am

JNJ

Johnson & Johnson's MARIPOSA study reveals that the RYBREVANT plus LAZCLUZE regimen outperforms osimertinib in treating lung cancer, showing better survival rates at three years.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:26 am